European authorities recommend marketing extension for Ozurdex

The European Union’s Committee for Medicinal Products for Human Use has recommended extending the marketing authorization for the dexamethasone 700 mcg intravitreal implant in applicator, according to an Allergan press release.Dexamethasone 700 mcg intravitreal implant (Ozurdex, Allergan) is indicated for adult patients with vision loss due to diabetic macular edema who are pseudophakic, or who are unable to undergo non-corticosteroid therapy.

Full Story →